In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates
Copyright © 2018 American Society for Microbiology..
Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, ≤1 μg/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 62(2018), 8 vom: 12. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Fangyou [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.09.2019 Date Revised 23.09.2019 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01031-18 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285360760 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285360760 | ||
| 003 | DE-627 | ||
| 005 | 20231225045258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01031-18 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0951.xml |
| 035 | |a (DE-627)NLM285360760 | ||
| 035 | |a (NLM)29891605 | ||
| 035 | |a (PII)e01031-18 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Fangyou |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2019 | ||
| 500 | |a Date Revised 23.09.2019 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 American Society for Microbiology. | ||
| 520 | |a Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, ≤1 μg/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a carbapenem resistance | |
| 650 | 4 | |a ceftazidime-avibactam | |
| 650 | 4 | |a hypervirulent Klebsiella pneumoniae | |
| 650 | 4 | |a susceptibility | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Azabicyclo Compounds |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a avibactam, ceftazidime drug combination |2 NLM | |
| 650 | 7 | |a Ceftazidime |2 NLM | |
| 650 | 7 | |a 9M416Z9QNR |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a carbapenemase-2, Klebsiella pneumoniae |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a Lv, Jingnan |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Siqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yi-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Bonomo, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Kreiswirth, Barry N |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 62(2018), 8 vom: 12. Aug. |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2018 |g number:8 |g day:12 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01031-18 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2018 |e 8 |b 12 |c 08 | ||